GO:0061098 positive regulation of protein tyrosine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061098 describes any process that increases the rate, frequency, or extent of protein tyrosine kinase activity, a central signaling event in metazoan biology.
• Protein tyrosine kinases (PTKs) are regulated by autophosphorylation, transphosphorylation, SH2/SH3 domain interactions, and ligand-induced receptor dimerization.
• Key PTK families include Src, Abl, Syk, JAK, RET, and PTK7, each with distinct roles in development, immunity, and cancer.
• Dysregulated positive regulation of PTK activity drives oncogenesis, inflammatory diseases, and developmental disorders, making PTKs major drug targets.
• CRISPR knockout, point-mutation knock-in, and overexpression models are essential to dissect causal roles of PTK regulators in disease.
• EDITGENE provides end-to-end CRISPR cell model services to study GO:0061098-related genes with publication-grade rigor.
Description
Protein tyrosine kinases (PTKs) are enzymes that catalyze the transfer of the gamma-phosphate of ATP to tyrosine residues on protein substrates, thereby initiating or modulating intracellular signaling cascades. The Gene Ontology term GO:0061098, positive regulation of protein tyrosine kinase activity, captures any process that increases the rate, frequency, or extent of this enzymatic activity. This regulation is fundamental to metazoan development, immune responses, and tissue homeostasis, and its dysregulation is a hallmark of many cancers and immune disorders. Understanding how PTK activity is positively regulated is therefore critical for both basic biology and therapeutic development.
positive regulation of protein tyrosine kinase activity At A Glance
| GO ID | GO:0061098 |
|---|---|
| GO term | positive regulation of protein tyrosine kinase activity |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Upregulation of tyrosine phosphorylation signaling |
| Related molecular function | protein tyrosine kinase activity (GO:0004713) |
| Related biological process | protein phosphorylation (GO:0006468) |
| Disease relevance | Cancer, immune disorders, developmental syndromes |
What Is GO:0061098?
GO:0061098 is a biological process term defined as any process that increases the rate, frequency, or extent of protein tyrosine kinase activity. In practice, this includes mechanisms such as autophosphorylation of receptor tyrosine kinases upon ligand binding, transphosphorylation within kinase complexes, allosteric activation by binding partners, and de-repression by phosphatases or inhibitory domains. It does not refer to the kinase activity itself (which is a molecular function) but to the regulatory events that enhance it.
Why Is positive regulation of protein tyrosine kinase activity Important in Cell Biology?
Positive regulation of protein tyrosine kinase activity is a central node in signal transduction, controlling cell proliferation, differentiation, migration, and survival. Because PTKs are frequently mutated or overexpressed in human diseases, understanding the mechanisms that enhance their activity provides direct insight into oncogenesis and identifies targets for small-molecule inhibitors. Moreover, the same regulatory principles apply to immune receptor signaling, where kinases such as Syk and JAK are essential for lymphocyte activation and cytokine responses.
• Drives oncogenic signaling in cancers such as chronic myeloid leukemia (BCR-ABL), lung cancer (RET fusions), and hepatocellular carcinoma (PTK7).
• Essential for T-cell antigen receptor signaling and adaptive immunity through Syk and JAK family kinases.
• Regulates developmental processes including Hedgehog signaling via DYRK2-mediated GLI2/GLI3 phosphorylation.
• Modulates cell death and survival decisions through Abl kinase activity.
• Provides validated drug targets: FDA-approved inhibitors for RET, JAK, and ALK (e.g., brigatinib).
• Serves as a paradigm for understanding allosteric and post-translational regulation of enzyme activity.
• Involved in metastasis and TGF-beta signaling in hepatocellular carcinoma via PTK7.
• Underpins precision medicine strategies that stratify patients by kinase activation status.
What Happens During positive regulation of protein tyrosine kinase activity?
Ligand-induced receptor dimerization and autophosphorylation
In simple terms: When a growth factor binds to a receptor kinase, two receptors pair up and activate each other by adding phosphate groups.
For receptor tyrosine kinases (RTKs), positive regulation often begins with ligand binding, which induces receptor dimerization and subsequent autophosphorylation of tyrosine residues in the activation loop and juxtamembrane region. This autophosphorylation increases kinase activity and creates docking sites for SH2-domain-containing proteins. For example, RET kinase is activated by ligand-induced dimerization in thyroid and lung cancers, and this mechanism is targeted by FDA-approved inhibitors.
Transphosphorylation within kinase complexes
In simple terms: Kinases can activate each other by swapping phosphate groups when they are close together.
Cytoplasmic tyrosine kinases such as Src and Syk are positively regulated by transphosphorylation. Src family kinases require phosphorylation of a tyrosine in the activation loop by another kinase or by autophosphorylation, while SH2 and SH3 domain interactions relieve autoinhibition. Syk is activated upon binding to phosphorylated ITAM motifs in immune receptors, leading to transphosphorylation and enhanced catalytic activity.
Allosteric activation and conformational changes
In simple terms: Binding of a partner protein can change the shape of a kinase to make it more active.
Positive regulation can occur through allosteric mechanisms. For instance, binding of the SH2 domain of Abl to phosphorylated partners can disrupt autoinhibitory interactions, increasing kinase activity. Similarly, DYRK2 kinase positively regulates Hedgehog signaling by phosphorylating GLI2/GLI3, which may involve conformational changes that enhance GLI transcriptional activity.
Phosphatase inhibition and de-repression
In simple terms: Blocking the enzymes that remove phosphates keeps kinases active longer.
Because tyrosine phosphorylation is reversible, positive regulation of PTK activity can also be achieved by inhibiting protein tyrosine phosphatases (PTPs). Although not directly a PTK activation event, the net effect is increased tyrosine phosphorylation. This principle is exploited in research to study kinase pathways, and some oncogenic mutations in PTPs lead to hyperactive PTK signaling.
Transcriptional and translational upregulation of PTKs
In simple terms: Cells can make more kinase protein to increase overall activity.
Increased expression of PTK genes, often through gene amplification or transcriptional activation, elevates the total pool of kinase molecules and thus enhances signaling output. For example, PTK7 is overexpressed in hepatocellular carcinoma and promotes metastasis via SOX9 regulation and TGF-beta signaling. This form of positive regulation is common in cancer and is a target for therapeutic intervention.
Key Genes Involved in GO:0061098 positive regulation of protein tyrosine kinase activity
The following genes encode proteins that are either tyrosine kinases or direct positive regulators of tyrosine kinase activity, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SRC | Non-receptor tyrosine kinase; regulated by SH2/SH3 domains | Prototype for understanding kinase autoinhibition and activation |
| ABL1 | Non-receptor tyrosine kinase; regulates cell death and proliferation | Target of imatinib in CML; model for oncogenic fusion kinases |
| SYK | Spleen tyrosine kinase; key mediator of immune receptor signaling | Essential for T-cell antigen receptor signaling; drug target in autoimmune diseases |
| JAK1/2/3 | Janus kinases; mediate cytokine receptor signaling | Targets of JAK inhibitors for inflammatory diseases |
| RET | Receptor tyrosine kinase; drives thyroid and lung cancers | FDA-approved inhibitors (e.g., selpercatinib) validate RET as oncogene |
| PTK7 | Pseudokinase with tyrosine kinase-like domain; regulates Wnt and TGF-beta | Promotes metastasis in hepatocellular carcinoma via SOX9 |
| DYRK2 | Dual-specificity tyrosine-regulated kinase; phosphorylates GLI2/GLI3 | Positive regulator of Hedgehog signaling |
| ALK | Anaplastic lymphoma kinase; fusion proteins in NSCLC | Target of brigatinib; exemplifies oncogenic kinase activation |
| EGFR | Receptor tyrosine kinase; activated by ligand-induced dimerization | Model for RTK autophosphorylation and drug resistance |
| PDGFR | Platelet-derived growth factor receptor; regulates cell growth | Classic example of RTK positive regulation |
| FGFR | Fibroblast growth factor receptor; involved in development and cancer | Mutations lead to constitutive kinase activation |
| KIT | Stem cell factor receptor; regulates hematopoiesis | Oncogenic mutations in gastrointestinal stromal tumors |
| LCK | Src-family kinase; essential for T-cell signaling | Model for SH2/SH3-mediated regulation |
| ZAP70 | Syk-family kinase; recruited to phosphorylated ITAMs | Critical for T-cell activation downstream of TCR |
| BTK | Bruton's tyrosine kinase; B-cell receptor signaling | Target of ibrutinib in B-cell malignancies |
| TYK2 | Janus kinase family member; mediates cytokine signaling | Target in psoriasis and autoimmune diseases |
| MET | Receptor tyrosine kinase; activated by HGF | Oncogenic driver in lung and gastric cancers |
| ROS1 | Receptor tyrosine kinase; fusion in NSCLC | Target of crizotinib and entrectinib |
How Is positive regulation of protein tyrosine kinase activity Regulated?
Positive regulation of protein tyrosine kinase activity is itself tightly controlled at multiple levels. Autophosphorylation and transphosphorylation provide rapid, reversible activation. Protein tyrosine phosphatases (PTPs) counteract kinase activity, and their inhibition or loss can enhance signaling. Transcriptional upregulation of PTK genes, as seen with PTK7 in hepatocellular carcinoma, increases the available kinase pool. Additionally, scaffolding proteins and lipid second messengers can localize kinases to membranes, promoting activation. In immune cells, cytokine and antigen receptor signaling dynamically regulate JAK and Syk family kinases. Pharmacological inhibitors of RET, JAK, and ALK demonstrate that these regulatory nodes are clinically actionable.
positive regulation of protein tyrosine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABL1 | Chronic myeloid leukemia | Knockout of BCR-ABL in K562 cells; point mutation of kinase domain |
| RET | Thyroid and lung cancer | Knock-in of RET fusion in HEK293; overexpression in Ba/F3 cells |
| PTK7 | Hepatocellular carcinoma metastasis | Knockout in HepG2; overexpression in HCC cell lines |
| SYK | Autoimmune and inflammatory diseases | Knockout in Jurkat T cells; point mutation of ITAM binding |
| JAK2 | Myeloproliferative neoplasms | Knock-in of V617F mutation in hematopoietic stem cells |
Cancer
Dysregulated positive regulation of PTK activity is a hallmark of many cancers. BCR-ABL fusion in chronic myeloid leukemia leads to constitutively active Abl kinase, which promotes proliferation and survival. RET point mutations and fusions drive thyroid and lung cancers, and FDA-approved RET inhibitors have transformed patient outcomes. PTK7 overexpression enhances metastasis in hepatocellular carcinoma through SOX9 and TGF-beta signaling. ALK fusions in non-small cell lung cancer are targeted by brigatinib, illustrating the clinical impact of understanding kinase activation.
Immune and inflammatory disorders
Syk and JAK family kinases are central to immune receptor signaling. Syk is required for T-cell antigen receptor signaling, and its dysregulation contributes to autoimmune diseases. JAK inhibitors are approved for rheumatoid arthritis and other inflammatory conditions, highlighting the therapeutic relevance of positive regulation of PTK activity. BTK, a Tec-family kinase, is a target in B-cell malignancies and autoimmune diseases.
Developmental disorders
DYRK2 positively regulates Hedgehog signaling by phosphorylating GLI2/GLI3, a pathway critical for embryonic development. Aberrant Hedgehog signaling due to altered kinase activity can lead to developmental syndromes and cancers such as medulloblastoma. Similarly, RTK signaling via FGFR and PDGFR is essential for organogenesis, and mutations cause skeletal and craniofacial disorders.
From positive regulation of protein tyrosine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate PTK regulator reduce kinase activity? | CRISPR knockout cell line (e.g., HEK293, HeLa) |
| Does a specific point mutation alter kinase activation? | Point-mutation knock-in via CRISPR (e.g., activation loop mutant) |
| Does a fusion kinase drive oncogenic transformation? | Knock-in of fusion gene (e.g., BCR-ABL) in primary cells |
| Where does the kinase localize and interact? | Tagged knock-in (e.g., GFP or HA tag) for imaging and IP |
| Does overexpression mimic disease phenotype? | Overexpression via lentiviral transduction or CRISPR activation |
| Which genes synergize with PTK activation? | CRISPR library screening with phospho-tyrosine readout |
How to Study the positive regulation of protein tyrosine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global tyrosine phosphorylation | Identify substrates and pathways |
| Western blot | Specific phospho-tyrosine levels | Validate kinase activation |
| Immunoprecipitation kinase assay | Enzymatic activity toward substrate | Measure intrinsic kinase activity |
| CRISPR knockout screen | Loss-of-function effects on kinase activity | Discover positive regulators |
| CRISPR activation screen | Gain-of-function effects | Identify enhancers of PTK signaling |
| FRET biosensor imaging | Real-time kinase activity | Study spatiotemporal dynamics |
| RNA-seq | Transcriptional changes | Assess downstream gene expression |
| Proximity ligation assay | Protein-protein interactions | Detect kinase-substrate complexes |
Phosphoproteomics
Mass spectrometry-based phosphoproteomics enables global quantification of tyrosine phosphorylation changes upon modulation of PTK activity. This method can identify direct substrates and downstream effectors, as demonstrated in studies of Src and Abl signaling.
Western blotting and immunoprecipitation
Phospho-specific antibodies against activation loop tyrosines (e.g., pY416 Src, pY397 FAK) are used to monitor kinase activation. Immunoprecipitation followed by kinase assays provides direct measurement of enzymatic activity.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens coupled with phospho-tyrosine staining or reporter assays can identify positive regulators of PTK activity. This approach has been used to uncover modulators of RTK signaling.
Live-cell imaging and FRET biosensors
Genetically encoded FRET biosensors for tyrosine kinase activity allow real-time visualization of kinase activation dynamics in living cells. This is particularly useful for studying rapid signaling events downstream of receptor activation.
How CRISPR Can Be Used to Study GO:0061098 positive regulation of protein tyrosine kinase activity
Knockout
CRISPR knockout of a candidate PTK or its regulator can abolish kinase activity and reveal its requirement for downstream signaling. For example, knocking out SYK in Jurkat cells impairs T-cell receptor signaling. Knockout models are essential for validating on-target effects of inhibitors.
Point Mutation
Point mutations in kinase domains (e.g., gatekeeper mutations) can confer resistance to inhibitors or constitutively activate kinases. CRISPR-mediated knock-in of such mutations allows precise modeling of clinical resistance, as seen with RET and ALK mutations.
Knock-in
Knock-in of fusion genes (e.g., BCR-ABL, EML4-ALK) or tagged kinases enables study of oncogenic activation and localization. This approach is invaluable for drug discovery and understanding kinase biology.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can elevate PTK levels to mimic gene amplification or transcriptional upregulation observed in cancers such as PTK7-overexpressing hepatocellular carcinoma.
How EDITGENE Supports positive regulation of protein tyrosine kinase activity Research
Researchers studying positive regulation of protein tyrosine kinase activity-related genes often need to determine whether a candidate gene is causally involved in kinase activation, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR cell model services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of protein tyrosine kinase activity research.
Frequently Asked Questions About positive regulation of protein tyrosine kinase activity
What is GO:0061098?
GO:0061098 is a Gene Ontology biological process term defined as any process that increases the rate, frequency, or extent of protein tyrosine kinase activity.
What genes are involved in positive regulation of protein tyrosine kinase activity?
Key genes include SRC, ABL1, SYK, JAK1/2/3, RET, PTK7, DYRK2, ALK, and others that encode tyrosine kinases or their direct activators.
How is protein tyrosine kinase activity positively regulated?
Mechanisms include ligand-induced dimerization and autophosphorylation, transphosphorylation, allosteric activation, phosphatase inhibition, and transcriptional upregulation.
What diseases are associated with dysregulated tyrosine kinase activity?
Cancers such as chronic myeloid leukemia, lung cancer, and hepatocellular carcinoma, as well as immune and inflammatory disorders.
What are the main methods to study positive regulation of PTK activity?
Phosphoproteomics, Western blotting, kinase assays, CRISPR screens, and FRET biosensors are commonly used.
Which PTK inhibitors are FDA-approved?
Inhibitors targeting RET, JAK, ALK (e.g., brigatinib), and BCR-ABL are approved for various cancers and inflammatory diseases.
How does Syk regulate T-cell signaling?
Syk is activated upon binding to phosphorylated ITAMs in the T-cell receptor complex, leading to transphosphorylation and downstream signaling.
What is the role of DYRK2 in Hedgehog signaling?
DYRK2 positively regulates Hedgehog signaling by phosphorylating GLI2/GLI3, enhancing their transcriptional activity.
Can CRISPR be used to model PTK-driven cancers?
Yes, CRISPR knockout, knock-in, and point mutation models are widely used to study oncogenic kinases and drug resistance.
How does PTK7 promote metastasis?
PTK7 promotes metastasis in hepatocellular carcinoma via SOX9 regulation and TGF-beta signaling.
Conclusion
GO:0061098, positive regulation of protein tyrosine kinase activity, is a fundamental biological process that governs signal transduction in health and disease. The interplay of autophosphorylation, transphosphorylation, allosteric regulation, and transcriptional control ensures precise kinase activation, while its dysregulation drives cancer, immune disorders, and developmental defects. Continued research using advanced CRISPR models and phosphoproteomic tools will uncover new therapeutic opportunities.
References
- 1. Yoshida S et al.. 2024. Positive regulation of Hedgehog signaling via phosphorylation of GLI2/GLI3 by DYRK2 kinase.. Proc Natl Acad Sci U S A 121(28):e2320070121 PMID: 38968120
- 2. Wang JY. 2000. Regulation of cell death by the Abl tyrosine kinase.. Oncogene 19(49):5643-50 PMID: 11114745
- 3. Liu X et al.. 1994. Biochemistry of the Src protein-tyrosine kinase: regulation by SH2 and SH3 domains.. Recent Prog Horm Res 49:149-60 PMID: 7511826
- 4. Roskoski R Jr. 2026. FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.. Pharmacol Res 229:108237 PMID: 42107510
- 5. Wong TLM et al.. 2023. Protein Tyrosine Kinase 7 (PTK7) Promotes Metastasis in Hepatocellular Carcinoma via SOX9 Regulation and TGF-β Signaling.. Cell Mol Gastroenterol Hepatol 15(1):13-37 PMID: 36202326
- 6. Latour S et al.. 1997. Regulation of T-cell antigen receptor signalling by Syk tyrosine protein kinase.. Mol Cell Biol 17(8):4434-41 PMID: 9234701
- 7. Thompson JE. 2005. JAK protein kinase inhibitors.. Drug News Perspect 18(5):305-10 PMID: 16193102
- 8. Markham A. 2017. Brigatinib: First Global Approval.. Drugs 77(10):1131-1135 PMID: 28597393
